Fig. 7

pDC orchestrate innate and adaptive CVA21 anti-tumor immunity. a. ICAM-1 expression on immune cell components from healthy donors (n = 3). b-e CD14⁺ monocytes and pDC (CD123⁺BDCA-2⁺) were depleted from whole PBMC (W.PBMC) prior to analysis. b. IFN-α secretion from whole or depleted PBMC, or isolated CD14⁺ cells and pDC, was measured by ELISA 48 h post-CVA21 treatment. c. CM was generated from whole or depleted PBMC, following treatment with 0.1 pfu/PBMC CVA21 for 48 h. The cytotoxicity of CM against kasumi-1 (i) and HL-60 (ii) cells after 96 h was evaluated by MTS assay. d. NK cell CD69 expression (i) and NK cell CD107a/b degranulation (ii) after treatment of whole of depleted PBMC with 0.1pfu/cell CVA21 for 48 h was determined. e. ICAM/KG-1 cells (±CVA21 and without addition of mDC) were used to prime CTL and PBMCs depleted of CD14⁺ monocytes or pDC were used as effector cells. Tumor-specific CTLs were detected using CD107a/b degranulation assays against cell targets. Error bars indicate SEM. *denotes statistical significance. n.s. = not significant